This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
New-onset refractory status epilepticus (NORSE) is a recently defined clinical entity which describes patients who present with severe generalized seizures of unclear etiology that occur in the context of a preceding febrile illness.1–3 These seizures are typically unresponsive to antiepileptic medications.
Case report.
A 26-year-old otherwise healthy right-handed man presented with generalized tonic-clonic seizures after a 1-week history of headache, fever, and myalgias. He was admitted to our intensive care unit for treatment and underwent continuous EEG monitoring for 77 days. On admission to our intensive care unit, the CSF contained 92 × 106 white blood cells (96% lymphocytes). Consistent with previous reports of NORSE, an exhaustive structural, infectious, toxic/metabolic, autoimmune, neoplastic, and paraneoplastic workup did not identify a clear underlying etiology (figure, A). IV infusions of propofol or thiopental were used to maintain the patient in either an electrographic burst suppression pattern or electrographic silence, while enteral antiepileptic medications were titrated to therapeutic doses (e.g., phenytoin, valproic acid, clobazam, topiramate, vigabatrin, phenobarbital, and levetiracetam) (figure, B). Attempts to wean IV antiepileptic drugs were met with recurrence of electrographic multifocal sharp transients, originating from either temporal lobe, which evolved into clinical and electrographic seizures.
Figure Laboratory investigations, imaging, and pathologic findings in a case of new-onset refractory status epilepticus
(A) Table of investigations performed to identify the underlying etiology of the …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen